Poland—Full of Potential
In the past five years, the Polish government has begun to recognize the potential of biotech with several initiatives to help new companies. It also established NewConnect, the alternative market of the Warsaw Stock Exchange, in 2007.
“With Poland’s entry to the EU, we have had access to more funding and expertise, and the Warsaw Stock Exchange is now the second most active market in Europe for IPOs.
“That coupled with Poland having a pool of talented yet underexploited scientists and a balanced economy with little debt means that unlike many other countries, we have the room for growth and investment,” commented Przewiezlikowski.
Even Poland’s most well-established pharmaceutical company, Polpharma, has in the past year begun to set up a separate biotech division at the Gdansk Science and Technology Park called Polpharma Biologics.
“Polpharma Biologics intends to be fully operational by 2012, with process development as well as a cGMP scale-up facility, which will allow manufacturing of clinical batches of our biological products,” said Piotr Lassota, Ph.D., scientific director of Polpharma Biologics.
“This is why we are recruiting now at the BioForum. We will have a staff of 45 scientists and supporting personnel developing and making biosimilars, as well as innovative products to treat cancer and CNS disorders. We plan to in-license some biological products at various stages of development to complement our portfolio.”
This new air of optimism in Poland has helped spawn a number of promising biotechs. These include Selvita, Proteon Pharmaceuticals and Mabion.
Selvita is developing clinical candidates to treat cancer and CNS and autoimmune disorders that originally came from research at Polish universities. The most promising candidates will later be commercialized with pharma partners.
Selvita hopes to be listed on NewConnect in 2011 and expects to move its first candidates to the clinic in 2012.
Roland Kozlowski, Ph.D., CEO of Lectus Therapeutics, a U.K. pharmaceutical company developing drug candidates to treat neuropathic pain, is a great supporter of CEE biotech. He maintains a commitment to CEE biotech through Life Science Biznes Consulting, a firm that assists CEE companies in raising capital, helps investors execute diligence, and helps western companies enter this market.
Mabion is another of the rising biotech stars in Poland. The company is developing monoclonal antibody biosimilars and hopes to have antibodies in clinical development in the next two years.
“We have 20 staff and have just moved into our new facilities, which we’ll use for cGMP manufacturing of our clinical candidate in the next few months,” said Slawomir Jaros, Ph.D., head of R&D.
“The good thing about starting the facility from scratch is that we are building our production technology using all the latest disposable bioprocess and purification systems, so we’ll maximize our production of clinical material by saving time on cleaning between production runs,” he continued.
“We are starting animal studies with one clinical monoclonal antibody candidate as a treatment for lymphoma, so our first product in trials is likely to be a rituximab biosimilar.”
Proteon Pharmaceuticals is developing some unusual products based on using bacteriophages as an alternative to antibiotics or chemical bactericides. The lead product, Bafasal®, is a mix of three different bacteriophages that specifically target and kill strains of Salmonella enterica serovar Enteritidis and Typhimurium.
“We have tested this product in a large-scale trial of 150 chicken broilers, where we added Bafasal in liquid form to their feed,” Arkadiusz Wojtasik, Ph.D., project director at Proteon, explained.
“In the trial, we showed that the phage passes through the gut of healthy chickens and only acts in those chickens infected with Salmonella. Since the use of antibiotics in animal feed is banned by the EU, this is a good, safe alternative method of preventing Salmonella infections in chicken broilers.
“We plan to look at producing a microencapsulated form and to registering this product at the end of this year. Maybe at some time in the future we will evaluate its possible preventive use in humans.”
Czech Biotech—Trailing Behind
Despite having a population size similar to Hungary, the Czech Republic is lagging behind in biotech. With around 20 biotech companies, typically employing 8 to 100 people, Czech biotechs are mostly CRO and R&D companies; very few are developing therapeutic products. The most well established is BioTest.
“We have been in business since 1999,” said Jan Zábský, CEO. “We supply preclinical testing for a number of local pharmas such as Polpharma, Celon Pharma, Medical University of Warsaw, Advance Research Center of Poland, Institute of Anorganic Industry Pszczyna, Adamed, and Mabion. Our focus now is to supply these services to companies across the rest of Europe, the U.S., and Asia.”
Why has the Czech Republic been slow to get on board with biotech? “One of the first industrially produced penicillins was made in the Czech Republic in 1949, but since then we have concentrated on industrial engineering and have neglected the biotech industry,” explained Marek Polach, manager of CzechBio, the association of Czech biotech companies.
“This has meant we don’t have any VCs with biotech expertise, which is a problem. However, the Czech government is now giving funding to centers of excellence in Prague and Brno and just launched a seed fund of €20,000 that biotechs can apply for. This is not much, but at least it may give some companies a start.”
With less than 10 biological drugs in the clinical stages of development, CEE’s biopharma industry is still in its infancy—especially when compared to the Boston cluster, which the CEE biotech region aspires to emulate.
Speakers and delegates at “BioForum” did cite a number of issues CEE biotechs still have to deal with if the CEE region is to increase its drug output. One difficulty is a lack of experienced and internationally focused management teams and investors to help commercialize the research properly.
“We lack management skills and have very few experienced people at the CSO, CEO, CFO, and BD level, and most VCs in this region do not understand biotech,” stated Duda. “It is much easier to raise money in the Bay Area than if you’re from Eastern Slovakia. Also, getting in the door of big pharma is very difficult if you’re from Central and Eastern Europe.”
To address this problem many at “BioForum” believe those CEE countries that are part of the European Union need to lobby their governments to implement EU initiatives like the YIC (Young Innovative Company) status. This allows young biotech companies to avoid paying any social costs for the first 15 years and tax on revenues for the first three profitable years.
“If we work together, the CEE region has the potential to catch up as long as we can attract some people with the required entrepreneurial skills,” Duda concluded. “We should look at putting in place programs like China and Korea have where those that have trained in the U.S. or Western Europe are enticed back to their native countries with incentives. Then I believe that seeing the CEE region beginning to function like the Boston cluster would be a more realistic prospect.”